A Comparison of Neutron Fields for BNCT

  • Jeffrey E. Woollard
  • Thomas E. Blue
  • Jacek Capala

Abstract

Previously, we have developed the in-phantom neutron field assessment parameters T and DTumor for the evaluation of epithermal neutron fields for use in BNCT.1 These parameters are based on an energy-spectrum-dependent neutron normal-tissue RBE2 and the treatment planning methodology of Gahbauer and his co-workers,3 which includes the effects of dose fractionation.

Keywords

Boron Polyethylene Fractionation Lalanine Dmax 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.E. Woollard, T.E. Blue, N. Gupta, and R.A. Gahbauer, “Development and Application of Neutron Field Optimization Parameters for an Accelerator-Based Neutron Source for Boron Neutron Capture Therapy”, Nucl. Tech., 155:100–112, (1996).Google Scholar
  2. 2.
    T.E. Blue, J.E. Woollard, N. Gupta, and R.A. Gahbauer, “Beam Design and Evaluation for BNCT,” Proc. of First Inter. Workshop on Accelerator-Based Neutron Sources for Boron Neutron Capture Therapy, Jackson, WY, Sept. 11–14, 1994, INEL Report Conference-940976, pp. 197–212, (1995).Google Scholar
  3. 3.
    N. Gupta, R.A. Gahbauer, T.E. Blue, and A. Wambersie, “Dose Prescription in Boron Neutron Capture Therapy,” Int. J. Radiat. Oncol. Biol. Phys., 28:1157–1166, (1994).PubMedCrossRefGoogle Scholar
  4. 4.
    H.B. Liu, D.D. Greenberg, J. Capala, and F.J. Wheeler, “An Improved Neutron Collimator for Brain Tumor Irradiations in Clinical Boron Neutron Capture Therapy”, Med. Phys., 23:2051–2060, (1996).PubMedCrossRefGoogle Scholar
  5. 5.
    J.A. Coderre, E.H. Elowitz, M. Chadha, R. Bergland, J. Capala, D.D. Joel, H.B. Liu, D.N. Slatkin, and A.D. Chanana, “Boron Neutron Capture Therapy for Glioblastoma Multiforme using p-boronophenylalanine and Epithermal Neutrons: Trial Design and Early Clinical Results”, J. Neuro. Oncol., 33:141–152,(1997).CrossRefGoogle Scholar
  6. 6.
    R.A. Gahbauer, R.G. Fairchild, J.H. Goodman, and T.E. Blue, “RBE in Normal Tissue Studies”, Boron Neutron Capture Therapy: Toward Clinical Trials of Glioma Treatment, D. Gabel and R. Moss (ed), Plenum Press, N.Y., 123–128, (1992).Google Scholar
  7. 7.
    D.L. Bleuel, S.V. Costes, R.J. Donahue, B.A. Ludewigt, and J. Vujic, “Neutronics Analysis of Three Beam-Filter Assemblies for an Accelerator-Based BNCT Facility”, Proceedings of the Topical Meeting on Nuclear Applications of Accelerator Technology, Albuquerque, NM., Nov. 16–20, 1997, pp. 502–507, (1997).Google Scholar
  8. 8.
    J.F. Briesmeister (ed.), “MCNP-A General Monte Carlo N-particle Transport Code, Version 4A,” LA-12625, Los Alamos National Laboratory (1993).Google Scholar
  9. 9.
    D.W. Nigg, F.J. Wheeler, D.E. Wessol, J. Capala, and M. Chadha, “Computational Dosimetry and Treatment Planning for Boron Neutron Capture Therapy”, J. Neuro. Oncol., 33:93–104, (1997).CrossRefGoogle Scholar
  10. 10.
    H. Frankhauser, and P.R. Gavin, “Summing Up: Clinical Papers”, in Advances in Neutron Capture Therapy, A.H. Soloway, R.F. Barth, and D.E. Carpenter (ed), Plenum Press, N.Y., 799–805, (1993).CrossRefGoogle Scholar
  11. 11.
    P.R. Gavin, S.L. Kraft, R. Huiskamp, and J.A. Coderre, “A Review: CNS Effects and Normal Tissue Tolerance in Dogs”, J. Neuro-Oncol., 33:71–80, (1997).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Jeffrey E. Woollard
    • 1
  • Thomas E. Blue
    • 1
  • Jacek Capala
    • 2
  1. 1.Nuclear Engineering ProgramThe Ohio State UniversityColumbusUSA
  2. 2.Medical DepartmentBrookhaven National LaboratoryUptonUSA

Personalised recommendations